1-3 of 3
Mike J Donio
Close
Sort by
Journal Articles

AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms

William Casey Wilson, John O Richards, Gabriela Andrejeva, Benjamin J Capoccia, Robyn J Puro, Mike J Donio, Ronald R Hiebsch, Arun K Kashyap, Daniel S Pereira
Journal: Blood
Blood (2021) 138 (Supplement 1): 2277.
https://doi.org/10.1182/blood-2021-152896
Published: 2021
Journal Articles

Pre-Clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia

Mike J Donio, W. Casey Wilson, PhD, Isra Darwech, Gabriela Andrejeva, PhD, Benjamin J Capoccia, PhD, Robyn J Puro, PhD, Arun K Kashyap, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-140528
Published: 2020
Journal Articles

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

William Casey Wilson, PhD, John Richards, PhD, Robyn J Puro, PhD, Gabriela Andrejeva, PhD, Ben J Capoccia, PhD, Mike J Donio, Ronald R Hiebsch, BS, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139655
Published: 2020